Absci Past Earnings Performance
Past criteria checks 0/6
Absci's earnings have been declining at an average annual rate of -24.6%, while the Biotechs industry saw earnings growing at 12.3% annually. Revenues have been growing at an average rate of 11.5% per year.
Key information
-24.6%
Earnings growth rate
28.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 11.5% |
| Return on equity | -62.8% |
| Net Margin | -1,933.6% |
| Next Earnings Update | 14 May 2024 |
Recent past performance updates
Recent updates
Absci: Differentiated Antibody Discovery Play
Feb 27Absci GAAP EPS of -$0.32 misses by $0.01, revenue of $1M misses by $0.68M
Aug 11Absci teams up to help develop antibody drugs for cancer
Jul 07Merck And Absci: AI-Driven Drug Development Deal Has Promise, But May Take Years To Pay Out
Jan 10IPO Day With Absci CEO Sean McClain - The Google Of Synthetic Biology (Video)
Jul 22Revenue & Expenses BreakdownBeta
How Absci makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 6 | -111 | 38 | 0 |
| 30 Sep 23 | 7 | -106 | 36 | 0 |
| 30 Jun 23 | 9 | -112 | 38 | 0 |
| 31 Mar 23 | 6 | -99 | 39 | 0 |
| 31 Dec 22 | 6 | -105 | 41 | 0 |
| 30 Sep 22 | 6 | -111 | 42 | 0 |
| 30 Jun 22 | 5 | -107 | 39 | 0 |
| 31 Mar 22 | 5 | -121 | 34 | 0 |
| 31 Dec 21 | 5 | -103 | 28 | 0 |
| 30 Sep 21 | 6 | -84 | 21 | 0 |
| 30 Jun 21 | 5 | -73 | 14 | 0 |
| 31 Mar 21 | 5 | -48 | 9 | 0 |
| 31 Dec 20 | 5 | -49 | 6 | 0 |
| 31 Dec 19 | 2 | -24 | 4 | 0 |
Quality Earnings: ABSI is currently unprofitable.
Growing Profit Margin: ABSI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ABSI is unprofitable, and losses have increased over the past 5 years at a rate of 24.6% per year.
Accelerating Growth: Unable to compare ABSI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ABSI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: ABSI has a negative Return on Equity (-62.76%), as it is currently unprofitable.